Tourmaline Bio's Participation in Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 -- Tourmaline Bio, Inc. (NASDAQ: TRML), a leading clinical biotechnology firm focused on developing innovative treatments for patients suffering from severe immune and inflammatory conditions, has announced that it will feature two significant poster presentations at the forthcoming 19th Annual Cardiometabolic Health Congress (CMHC). This event is scheduled to take place from October 17 to 19, showcasing cutting-edge research in cardiovascular health.
Showcasing Critical Research
The posters presented by Tourmaline Bio will underline the company's ongoing dedication to enhancing the understanding of inflammatory cardiovascular risk and explore potential therapeutic mechanisms associated with IL-6 inhibition. This focus aligns with Tourmaline's mission of improving patient outcomes through transformative therapies.
Announcing the Posters
One of the featured posters will delve into the utilization of high-sensitivity C-reactive protein testing for both primary and secondary atherosclerotic cardiovascular disease (ASCVD) prevention.
Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention
Authors: Emil deGoma, MD; Yung Chyung, MD; John Walsh, MD; C. William Pike, MD; Jananee Muralidharan, MD; Vincent Marino; J. Craig Davis; Saurabh Gombar, MD, PhD; Michael D. Shapiro, DO, MCR.
Exploring IL-6 Inhibition Effects
The second poster will provide insights into the effects of IL-6 inhibition on lipoprotein(a) levels, drawing from a systematic review and meta-analysis, showcasing the ongoing research into cardiovascular health.
Title: Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis
Authors: Saeid Mirzai, DO; Emil deGoma, MD; John Walsh, MD; Raya Mahbuba, MSc; Yung Chyung, MD; Michael D. Shapiro, DO, MCR.
About Tourmaline Bio
Tourmaline Bio is committed to developing groundbreaking therapies aimed at improving the lives of patients faced with transformative immune and inflammatory diseases. The company’s lead product, pacibekitug (also known as TOUR006), showcases significant potential in treatment innovation.
Understanding Pacibekitug
Pacibekitug is an innovative, long-acting, fully-human anti-IL-6 monoclonal antibody that exhibits unique properties such as a remarkably long half-life, low immunogenicity, and high binding affinity to IL-6. The efficacy and safety of pacibekitug have been evaluated in about 450 participants through six completed clinical trials, focusing primarily on autoimmune conditions. Tourmaline is advancing the development of pacibekitug for applications such as thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), among other potential indications in the pipeline.
Company Contacts for More Information
For additional inquiries about Tourmaline Bio and the upcoming presentations at the CMHC, Media Contact: Sarah Mishek from Scient PR can be reached via email at SMishek@ScientPR.com.
For investor-related questions, Lee M. Stern from Meru Advisors is the contact person, available at lstern@meruadvisors.com.
Frequently Asked Questions
What are the main focus areas for Tourmaline Bio at the congress?
Tourmaline Bio will showcase its ongoing research on inflammatory cardiovascular risk and therapeutic mechanisms surrounding IL-6 inhibition.
What is pacibekitug?
Pacibekitug is a long-acting, fully-human anti-IL-6 monoclonal antibody with the potential for treating immune and inflammatory diseases.
How many participants have been involved in clinical trials of pacibekitug?
Pacibekitug has been studied in approximately 450 participants across six completed clinical trials.
What conditions is Tourmaline targeting with pacibekitug?
The initial focus for pacibekitug includes thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD).
Where can I find more information about Tourmaline Bio's research?
More information can be obtained by reaching out to the media contact or by visiting the official website of Tourmaline Bio.
